Serafin Morales Murillo
Grado: Doctor/a
973 70 53 03
smorales.lleida.ics(ELIMINAR)@gencat.cat
ResearcherID: http://www.researcherid.com/rid/L-7216-2019
Publicaciones
-
Fullana, B; Morales, S; Petit, A; Alay, A; Verdaguer, H; Climent, F; Navarro-Perez, V; Cejuela, M; Galvan, P; Gumà, A; Llombart-Cussac, A; Cordero, D; Casanovas, O; Prat, A; Gil-Gil, M; Pernas, S
Neoadjuvant sunitinib plus exemestane in post-menopausal women with hormone receptor-positive/HER2-negative early-stage breast cancer (SUT_EXE-08): a phase I/II trial
SCIENTIFIC REPORTS 14 -. .
-
Alés-Martínez, JE; Balmaña, J; Sánchez-Rovira, P; Bofill, FJS; Sáenz, JAG; Pimentel, I; Morales, S; Fernández-Abad, M; Martínez, AL; Ferrer, N; Zamora, P; Bermejo, B; Diaz-Redondo, T; López-Ceballos, MH; Galán, M; Pérez-Escuredo, J; Calabuig, L; Sampayo, M; Pérez-Garcia, JM; Cortés, J; Llombart-Cussac, A
Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study
BREAST 77 -. .
-
Freyer, G; Martinez-Jañez, N; Kukielka-Budny, B; Ulanska, M; Bourgeois, H; Muñoz, M; Morales, S; Calero, JB; Cortesi, L; Pintér, T; Palácová, M; Cherciu, N; Petru, E; Ettl, J; de Almeida, C; Villanova, G; Raymond, R; Minh, CTT; Rodrigues, A; Cazzaniga, ME
Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study
BREAST 74 103681-103681. .
-
Martinez-Jañez, N; Ezquerra, MB; Sanchez, LMM; Carrasco, FH; Torres, AA; Morales, S; Ortega, PT; Gil, VLO; Sampedro, T; Conejero, RA; Calvo-Martinez, L; Galve-Calvo, E; López, R; de la Pena, FA; Lopez-Tarruella, S; de Araguiz, BAHF; Ruiz, LB; Cardenas, TM; Chacon, JI; Antón, FM
First-line therapy with palbociclib in patients with advanced HR+/HER2- breast cancer: The real-life study PALBOSPAIN
BREAST CANCER RESEARCH AND TREATMENT 206 57-65. .
-
Cescon DW; Hilton J; Morales Murilo S; Layman RM; Pluard T; Yeo B; Park IH; Provencher L; Kim SB; Im YH; Wyce A; Krishnatry AS; Hicks K; Zhang Q; Barbash O; Khaled A; Horner T; Dhar A; Oliveira M; Sparano JA
A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer.
CLINICAL CANCER RESEARCH 30 334-343. .
-
Pont, M; Marques, M; Sorolla, MA; Parisi, E; Urdanibia, I; Morales, S; Salud, A; Sorolla, A
Applications of CRISPR Technology to Breast Cancer and Triple Negative Breast Cancer Research
Cancers 15 -. .
-
Schmid P; Cortes J; Joaquim A; Jañez NM; Morales S; Díaz-Redondo T; Blau S; Neven P; Lemieux J; García-Sáenz JÁ; Hart L; Biyukov T; Baktash N; Massey D; Burris HA 3rd; Rugo HS
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.
BREAST CANCER RESEARCH 25 67-67. .
-
Martín M; Zielinski C; Ruiz-Borrego M; Carrasco E; Ciruelos EM; Muñoz M; Bermejo B; Margelí M; Csöszi T; Antón A; Turner N; Casas MI; Morales S; Alba E; Calvo L; de la Haba-Rodríguez J; Ramos M; Murillo L; Santaballa A; Alonso-Romero JL; Sánchez-Rovira P; Corsaro M; Huang X; Thallinger C; Kahan Z; Gil-Gil M
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
EUROPEAN JOURNAL OF CANCER 168 12-24. .
-
Marques, M; Sorolla, MA; Urdanibia, I; Parisi, E; Hidalgo, I; Morales, S; Salud, A; Sorolla, A
Are Transcription Factors Plausible Oncotargets for Triple Negative Breast Cancers?
Cancers 14 -. .
-
Ocaña A; Chacon, JI; Calvo, L; Anton, A; Mansutti, M; Albanell, J; Martinez, MT; Lahuerta, A; Bisagni, G; Bermejo, B; Semiglazov, V; Thill, M; Chan, ARE; Morales, S; Herranz, J; Tusquets, I; Chiesa, M; Caballero, R; Valagussa, P; Bianchini, G; Alba, E; Gianni, L
Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.
Frontiers in oncology 11 827625-827625. .
-
Yao, HM; Jones, SR; Morales, S; Moosavi, S; Zhang, J; Freyman, A; Ottery, FD
Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer
CANCER CHEMOTHERAPY AND PHARMACOLOGY 88 1033-1048. .
-
Kahan, Z; Gil-Gil, M; Ruiz-Borrego, M; Carrasco, E; Ciruelos, E; Munoz, M; Bermejo, B; Margeli, M; Anton, A; Casas, M; Csoszi, T; Murillo, L; Morales, S; Calvo, L; Lang, I; Alba, E; de la Haba-Rodriguez, J; Ramos, M; Lopez, IA; Gal-Yam, E; Garcia-Palomo, A; Alvarez, E; Gonzalez-Santiago, S; Rodriguez, CA; Servitja, S; Corsaro, M; Rodrigalvarez, G; Zielinski, C; Martin, M
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study
EUROPEAN JOURNAL OF CANCER 156 70-82. .
Proyectos
- Development of Computer Application (Apps) for Information and Monitoring of Patients with Breast Cancer at the Hospital Arnau de Vilanova De Lleida
- SELECCIÓN DE TRATAMIENTO CON QUIMIOTERAPIA NEOADYUVANTE EN PACIENTES CON CÁNCER DE MAMA EN ESTADIO PRECOZ Y CON RECEPTORES HORMONALES POSITIVOS MEDIANTE LA DETERMINACIÓN DE LA PLATAFORMA ONCOTYPE, CF DNA EN SANGRE PERIFÉRICA Y CAMBIOS DEL MARCADOR KI67 EN TEJIDO TUMORAL.
- Cáncer de mama: utilidad pronóstica de los Perfiles de Expresión Proteica en pacientes con tumor residual viable (>1.0 cm) tras quimioterapia neoadyuvante
